Minimal benefit of tonsillectomy in T1-T2 tonsillar squamous cell carcinoma treated with chemoradiotherapy  by Chao, Yun-Ting et al.
Available online at www.sciencedirect.comScienceDirect
Journal of the Chinese Medical Association 79 (2016) 570e576
www.jcma-online.comOriginal Article
Minimal benefit of tonsillectomy in T1-T2 tonsillar squamous cell
carcinoma treated with chemoradiotherapy
Yun-Ting Chao a, Ling-Wei Wang b, Pen-Yuan Chu a,c, Muh-Hwa Yang d,e,f,g, Yen-Bin Hsu a,c,
Tsung-Lun Lee a,c, Yi-Fen Wang a,c, Shyh-Kuan Tai a,c,d,e,*
a Department of Otolaryngology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC
b Cancer Center, Taipei Veterans General Hospital, Taipei, Taiwan, ROC
c Department of Otolaryngology, National Yang-Ming University, Taipei, Taiwan, ROC
d Infection and Immunity Research Center, National Yang-Ming University, Taipei, Taiwan, ROC
e Immunology Center, Taipei Veterans General Hospital, Taipei, Taiwan, ROC
f Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan, ROC
g Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC
Received January 26, 2016; accepted April 1, 2016AbstractBackground: Chemoradiotherapy (CRT) has become the mainstay of treatment for tonsillar squamous cell carcinoma (SCC). Pre-CRT tonsil-
lectomy is frequently performed, mostly for small primary tumors (T1-T2). However, the benefits of pre-CRT tonsillectomy remain unclear.
Methods: A retrospective review was performed in 66 patients with T1-T2 tonsillar SCCs treated by CRT from 1997 to 2009. The efficacy of pre-
CRT tonsillectomy was analyzed with regard to oncological and functional outcomes.
Results: Thirty patients (45.5%) received tonsillectomy (pre-CRT tonsillectomy group), and 36 patients (54.5%) did not (CRT group). Except for
a trend toward more T1 cases (33.3% vs. 13.9%, p ¼ 0.061) and significantly less chemotherapy use (60% vs. 86.1%, p ¼ 0.016) in the pre-CRT
tonsillectomy group, there were no differences between the two groups in terms of age, gender, N classification (nodal status), overall stage,
radiation dose, duration, or technique. In the pre-CRT tonsillectomy group, eight cases (26.7%) achieved an adequate operative margin judged by
the surgeon, and only one (12.5%) had a negative pathological margin. In long-term follow-up, there were no statistically significant differences
between the two groups regarding local (93.3% vs. 91.7%, p ¼ 0.82) or regional control (93.3% vs. 94.4%, p ¼ 0.84). The pre-CRT tonsil-
lectomy group did not have a better 5-year disease-specific survival rate (83.3% vs. 94.4%, p ¼ 0.177) or 5-year overall survival rate (70% vs.
94.4%, p ¼ 0.017). There were no differences in complications or functional results (feeding tube and tracheostomy dependence), and quality of
life demonstrated no significant difference.
Conclusion: Pre-CRT tonsillectomy contributes little to oncological and functional outcomes in patients with T1-T2 tonsillar SCC.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Tonsillar squamous cell carcinoma (SCC) is the most
common type of oropharyngeal cancer, and its incidence has
been reported to be increasing in Western countries along with
the prevalence of human papilloma virus (HPV) infection.1,2
Early tonsillar SCCs can be treated by either surgery or
radiotherapy (RT), while advanced cases usually require asevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
Table 1
Patient characteristics.
Pre-CRT
tonsillectomy
(n ¼ 30)
CRT
(n ¼ 36)
p
Age 56.8 55.6 0.680
Gender 0.486
Male 22 (73.3%) 29 (80.6%)
Female 8 (26.7%) 7 (19.4%)
T classification 0.061
T1 10 (33.3%) 5 (13.9%)
T2 20 (66.7%) 31 (86.1%)
N classification 0.352
N0 13 (43.3%) 9 (25.0%)
N1 2 (6.7%) 6 (16.7%)
N2 14 (46.7%) 20 (55.6%)
N3 1 (3.3%) 1 (2.8%)
Overall stage
Stage IeII 13 (43.3%) 9 (25%) 0.116
Stage IIIeIV 17 (56.7%) 27 (75%)
CRT ¼ chemoradiotherapy.
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adjuvant therapy or chemoradiotherapy (CRT). Because of
excellent radiosensitivity at this tumor subsite, CRT has
become the mainstay of treatment for tonsillar SCCs in recent
years, and the use of open surgery has declined.3,4 However,
optimal treatment strategy remains under debate.5
Despite the common use of definitive CRT as the treatment
for tonsillar SCC, tonsillectomy is still frequently performed
first, mostly for T1-T2 tumors. Common reasons for tonsillec-
tomy before CRT include: (1) tissue diagnosis for occult pri-
mary tumors presenting with metastatic neck disease or as
asymmetric tonsils; (2) the feasibility of transoral tumor
removal; (3) the belief that optimal oncological outcomes with
the combination of tonsillectomy reduce tumor burden before
CRT treatment. Yildirim et al6 reported excellent oncological
outcomes in 120 patients who underwent tonsillectomies fol-
lowed by RT. However, there was no control group for com-
parison in their study. Holliday et al7 analyzed the Surveillance
Epidemiology and End Results registry, and found that patients
with early tonsillar SCC may have had better survival benefits
with pre-CRT tonsillectomy compared with those who received
a biopsy only. However, their study did not include data on
locoregional control or functional outcomes.
Therefore, the benefits of pre-CRT tonsillectomy require
further clarification, especially for small T1-T2 tonsillar SCCs
for which transoral removal could be feasible. The aim of this
study was to evaluate the efficacy of pre-CRT tonsillectomy in
a retrospective cohort of patients with T1-T2 tonsillar SCCs.
The oncological and functional outcomes were analyzed to
determine the effect of pre-CRT tonsillectomy before defini-
tive CRT treatment.
2. Methods2.1. Population selectionTable 2
Chemoradiotherapy treatment data.
Pre-CRT
tonsillectomy
(n ¼ 30)
CRT
(n ¼ 36)
p
RT dose (Gy) 67.74 68.09 0.763
RT duration (d) 49.4 51.5 0.136
RT technique 0.380
IMRT 16 (53.3%) 19 (52.8%)This retrospective analysis included patients with T1-T2
tonsillar SCCs treated between 1997 and 2009 in Taipei Vet-
erans General Hospital. Approval for this study was obtained
from the Institutional Review Board (2012-03-037BC). One
hundred and sixteen consecutive patients were included.
Forty-eight patients were excluded, including 21 treated with
surgery alone, four with open surgery including man-
dibulotomy or mandibulectomy, two with chemotherapy only,
and 21 with transoral surgery and neck dissection. Another
two patients were excluded for distant metastasis (DM) at
diagnosis. The remaining 66 patients treated with CRTwith or
without pre-CRT tonsillectomy were included in this study.3D 5 (16.7%) 11 (30.9%)
2D 6 (20%) 5 (13.9%)2.2. Patient characteristics and tumor status
Not determined 3 (10%) 1 (2.8%)
Chemotherapy 0.016
Yes 18 (60%) 31 (86.1%)
No 12 (40%) 5 (13.9%)
Median follow-up
time (mo)
65.5 (range 7e187) 56 (range 6e126) 0.743
CRT ¼ chemoradiotherapy; IMRT ¼ intensity modulated radiotherapy;
RT ¼ radiotherapy.Tumors were staged according to the 2002 criteria of the
American Joint Committee on Cancer, and the patient char-
acteristics are summarized in Table 1. Thirty patients (45.5%)
received pre-CRT tonsillectomy (pre-CRT tonsillectomy
group) and the other 36 (54.5%) received CRT only (CRT
group). There was a trend toward more T1 tumors in the pre-CRT tonsillectomy group compared with the CRT group
(33.3% vs. 13.9%, p ¼ 0.061). Otherwise, no statistically
significant differences were observed between the two groups
in terms of age, gender, N classification or overall stage.2.3. Treatment plansThe CRT treatment data are shown in Table 2. RT was
delivered at 2 Gy per fraction, 5 d/wk, for a total dose of
52e75 Gy to the primary site and/or positive neck level, and
50 Gy to the N0 neck level. Both sides of the neck were
included in treatment portals, and RT was administered as
6 MV X-rays from a linear accelerator. Accelerated fraction-
ation of the RT was not performed. There were no differences
in RT between the two groups, including total dosage, dura-
tion, and technique (Table 2).
Induction or concurrent cisplatin-based chemotherapy was
given to some patients. Induction chemotherapy (ICT) was
delivered in two courses; the regimen mainly consisted of
cisplatin (60 mg/m2) and 5-fluorouracil (600 mg/m2/
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(20 mg/m2/d) and 5-fluorouracil (600 mg/m2/d) were delivered
for 4 days every 3 weeks concomitantly with the RT. Chemo-
therapy was given less frequently in the pre-CRT tonsillectomy
group than in the CRT group (60% vs. 86.1%, p ¼ 0.016).
Among the 18 patients in the pre-CRT tonsillectomy group who
received chemotherapy, only four (22.2%) underwent ICT. In
contrast, 14 (45.2%) of the 31 patients in the CRT group who
received chemotherapy underwent ICT. The median follow-up
time was 65.5 months for the pre-CRT tonsillectomy group
and 56 months for the CRT group ( p ¼ 0.743).2.4. Tissue diagnosis status and margin of tonsillectomyIn the CRT group, tissue diagnosis was established by punch
biopsy at our clinic. In the pre-CRT tonsillectomy group, the
diagnosis of SCC was pathologically proven in six patients
(20%) prior to tonsillectomy. Among the other 24 patients
(80%), seven underwent tonsillectomy to identify the primary
tumors with metastatic neck disease, and 17 underwent tonsil-
lectomy directly with grossly visible tonsillar tumors. Tonsil-
lectomy was performed by dissection with either electrocautery
or cold instruments along the tonsil capsule. When gross inva-
sion of the tonsil capsule was found, the dissection was carried
out including a cuff (2e4 mm) of surrounding soft tissue to
remove the tumor as completely as possible.
The margin status of the tonsillectomy specimen was ob-
tained according to the surgical records and pathology reports.
The operative margin was judged by the surgeon and classified
into adequate, inadequate, and not mentioned. A negative
pathological margin was defined as no tumor cells being found
within 2 mm from the cut margin. A close margin was defined
as tumor cells or cell dysplasia within 2 mm of the cut margin,
and a positive margin was defined as the presence of tumor
cells at the resection border of the specimen.2.5. Outcome measurementsTable 3
Operative and pathological margin statuses.
Pathological margin Operative margin
Adequate Inadequate Not mentioned
Negative 1 (12.5%) 0 1 2 (6.7%)
Closea 4 (50%) 0 4 8 (26.7%)
Positive 3 (37.5%) 1 5 9 (30%)
Not determined 0 3 8 11 (36.7%)
Total 8 (26.7%) 4 (13.3%) 18 (60%) 30
a Close margin: <2 mm from cut margin or margin dysplastic change.Disease-specific survival (DSS) and overall survival (OS)
were calculated using the Kaplan-Meier product limit method.
Follow-up times were defined as the duration between the date
of treatment initiation and events or last contact. OS was
defined as the time from diagnosis of the primary cancer to
death by any causes. DSS was defined as the time to death
from cancer or treatment-related events. Functional results
were determined by the dependence of feeding and tracheos-
tomy tubes at >6 months after completion of treatment. Major
complications were defined as treatment-related events, such
as massive bleeding, neutropenic fever, or osteoradionecrosis,
which necessitated a second operation, prolonged hospitali-
zation, or were life-threatening.
Quality of life (QOL) assessments were only available for
15 patients (six in the pre-CRT tonsillectomy group and nine
in the CRT group) at posttreatment 1 year, using the European
Organization for Research and Treatment of Cancer Core
QOL questionnaire (EORTC QLQ-C30) and head- and neck-
specific QOL questionnaire (EORTC QLQ-H&N35).82.6. Statistical analysesAll analyses were performed using PASW statistical soft-
ware version 18 (SPSS Inc., Chicago, IL, USA). Differences in
categorical variables between the two groups were determined
using Pearson's Chi-square or Fischer's exact test. The Mann-
Whitney U test was used to compare the means because of
non-normality in the distribution. DSS and OS were compared
by the log-rank test. All tests were two-sided, and the results
were considered significant at p < 0.05.
3. Results3.1. Margin status in the pre-CRT tonsillectomy groupAmong all patients in the pre-CRT tonsillectomy group, the
operative margin was considered to be adequate in eight cases
(26.7%) and inadequate in four cases (13.3%). In the other 18
cases (60%), the status of the operative margin was not
mentioned. Under pathological examination, a negative path-
ological margin was achieved in only two cases (6.7%), while
close and positivemargins were noted in eight (26.7%) and nine
(30%) cases, respectively. In the other 11 cases (36.7%), the
pathological margin was not determined due to fragmentation
of the tumor specimen. Of note, among the eight patients whose
operative margin was considered to be adequate, only one
(12.5%) had a negative pathological margin (Table 3).3.2. Oncological outcomesThe oncological and functional outcomes are summarized
in Table 4. After long-term follow-up, the disease control rates
were almost equivalent between the two groups. There was no
significant difference in 5-year DSS rate between the pre-CRT
tonsillectomy and CRT groups (83.3% vs. 94.4%, p ¼ 0.177)
(Fig. 1). However, a trend toward a higher rate of DM (10%
vs. 0%, p ¼ 0.059) and a poorer 5-year OS (70.0% vs. 94.4%,
p ¼ 0.017) were observed in the pre-CRT tonsillectomy group.3.3. Complications and functional outcomesLong-term complications and functional outcomes are lis-
ted in Table 4. The incidence rates of major complications
were 20.0% and 16.7% in the pre-CRT tonsillectomy group
and CRT group, respectively ( p ¼ 0.727). Of the six cases
Fig. 1. The Kaplan-Meier curves of disease-specific survival (DSS) of pre-
CRT tonsillectomy (n ¼ 30) and CRT (n ¼ 36) groups in a T1-T2 tonsillar
squamous cell carcinoma cohort. CRT ¼ chemoradiotherapy; DSS ¼ disease-
specific survival.
Table 5
Posttreatment 1 year quality of life.
Pre-CRT
tonsillectomy
(n ¼ 6)
CRT
(n ¼ 9)
p
EORTC QLQ-C30
Global health scale 66.5 ± 36.2 77.7 ± 16.6 0.72
Physical function 90.8 ± 10.2 94.8 ± 7.3 0.38
Role function 94.3 ± 13.9 92.6 ± 12.1 0.65
Emotional function 88.8 ± 10.2 91.7 ± 22.2 0.13
Cognitive function 86.2 ± 16.2 92.6 ± 12.1 0.42
Social function 88.7 ± 17.6 85.2 ± 22.7 0.89
Symptom scale
Fatigue 11.0 ± 13.9 8.6 ± 13.2 0.64
Nausea/vomiting 2.8 ± 6.9 0 0.22
Pain 11.2 ± 13.6 11.1 ± 18.6 0.74
Single item
Dyspnea 0 0 >0.99
Insomnia 33.2 ± 36.5 7.3 ± 14.6 0.77
Appetite loss 0 3.7 ± 11 0.41
Constipation 22.2 ± 40.4 11.0 ± 23.3 0.60
Diarrhea 0 0 >0.99
Financial difficulties 16.5 ± 18.1 11.1 ± 33.3 0.17
EORTC QLQ-H&N35
Pain 9.7 ± 15.1 8.2 ± 11.0 0.75
Senses problems 12.5 ± 8.9 23.1 ± 9.8 0.06
Speech problems 11.0 ± 12.0 11.0 ± 18.2 0.61
Social eating 11.0 ± 14.5 13.9 ± 13.8 0.80
Social contact 5.5 ± 13.4 5.2 ± 10.5 0.93
Less sexuality 38.8 ± 49 7.3 ± 14.6 0.18
Teeth 33.2 ± 36.5 22.1 ± 37.2 0.37
Opening mouth 5.5 ± 13.5 11.0 ± 23.3 0.74
Dry mouth 44.2 ± 40.2 55.2 ± 37.2 0.58
Sticky saliva 22.0 ± 26.9 62.7 ± 38.9 0.49
Coughing 16.5 ± 18.1 3.7 ± 11.0 0.11
Felt ill 5.5 ± 13.5 11.0 ± 16.5 0.49
Pain killers 16.7 ± 40.8 11.1 ± 33.3 0.77
Nutrition supplements 33.3 ± 51.6 33.3 ± 50.0 >0.99
Feeding tube 0 0 >0.99
Weight loss 16.7 ± 40.8 0 0.22
Weight gain 66.7 ± 51.6 33.3 ± 50.0 0.22
Data are expressed as mean ± standard deviation.
CRT ¼ chemoradiotherapy; EORTC ¼ European Organization for Research
and Treatment of Cancer; QLQ ¼ quality of life questionnaire.
Table 4
Patient outcomes.
All
(n ¼ 66)
Pre-CRT
tonsillectomy
(n ¼ 30)
CRT
(n ¼ 36)
p
Disease control
Local control 92.4% 93.3% 91.7% 0.82
Regional control 93.9% 93.3% 94.4% 0.842
DM 3 (4.5%) 3 (10%) 0 0.059
Survival
5-y DSS 89.4% 83.3% 94.4% 0.177
5-y OS 83.3% 70.0% 94.4% 0.017
Complication 12 (18.2%) 6 (20.0%) 6 (16.7%) 0.727
Functional results
Tube feeding 2 (3.0%) 2 (6.7%) 0 0.203
Tracheostomy 0 0 0
CRT ¼ chemoradiotherapy; DM ¼ distant metastasis; DSS ¼ disease-specific
survival; OS ¼ overall survival.
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involved massive postoperative bleeding, one from the ton-
sillectomy wound and the other from ruptured esophageal
varices owing to procedure-related stress. The other compli-
cations in this group included two of mandibular osteor-
adionecrosis, one of neutropenic fever during ICT, and one of
aspiration pneumonia. In the CRT group, neutropenic fever
during concurrent CRT occurred in three patients, and acute
renal failure and pneumonia in one and two patients,
respectively.
Respiratory and swallowing functional outcomes were
evaluated by tracheostomy and feeding tube dependence. No
patient was tracheostomy-dependent in either treatment group,
and feeding tube dependency was not significantly different
between the pre-CRT tonsillectomy and CRT groups (6.7% vs.0%, p ¼ 0.203). Of the 15 patients who had available data on
1-year QOL results posttreatment, there was no significant
difference between the two groups in global health status, all
functional scales, and all symptom and single-item scales on
the EORTC QLQ-C30 questionnaire (Table 5). There were
also no significant differences in most items of the EORTC
QLQ H&N 35 questionnaire between the two groups, except
for a trend toward fewer sense problems ( p ¼ 0.06) in the pre-
CRT tonsillectomy group compared with the CRT group.
4. Discussion
In this study, the results of CRT treatment with or without
pre-CRT tonsillectomy were compared in a cohort of 66 pa-
tients with T1-T2 tonsillar SCCs. Our data indicated that pre-
CRT tonsillectomy did not contribute to additional benefits
regarding disease control, survival, complications, functional,
or QOL outcomes. The locoregional control rates were higher
574 Y.-T. Chao et al. / Journal of the Chinese Medical Association 79 (2016) 570e576than 90% in both groups. Consistent with our results, Men-
denhall et al9 reported 503 tonsillar SCC patients in whom
CRT achieved 88% and 84% local control rates in T1 and T2
cases, respectively. Reported series of intensity-modulated
radiation therapy also achieved comparable results.10e13
Taken together; these data indicate that CRT already pro-
vides excellent treatment results for patients with T1-T2
tonsillar SCCs.
In this retrospective study, we considered pre-CRT tonsil-
lectomy to be a debulking biopsy procedure, because adequate
surgical margins were seldom achieved in the pre-CRT ton-
sillectomy group (Table 3). CRT was considered as the
definitive treatment for T1-T2 tonsillar SCCs in this study,
given that patients who received pre-CRT neck dissection
were excluded and the RT dose in both treatment groups was
equivalent (Table 2). Poor surgical exposure in a conventional
tonsillectomy setting may be the main reason why 56.7% of
the cases in the pre-CRT tonsillectomy group, not including
36.7% with an undetermined margin status, did not achieve a
negative pathological margin, especially in the area near the
lower pole of the tonsillar fossa and the base of the tongue. It
is worth noting that most adequate operative margins judged
by the surgeon were not consistent with the final negative
pathological margins. Moreover, the tonsillectomy specimens
were frequently poorly orientated due to fragmentation,
making it difficult to determine the pathological margin in
more than one third of the cases (Table 3).
It has been reported that transoral lateral oropharyngectomy
using conventional or robotic instruments can achieve a high
rate (>85%) of negative pathological margin,14e18 and dein-
tensification by omitting the use of chemotherapy or reducing
the dose of RT.16,18 Further studies are needed to elucidate
whether these modern surgical techniques contribute to
improved CRT treatment results for T1-T2 tonsillar SCCs. In
the study by Yildirim et al,6 tonsillectomies followed by RT
achieved excellent oncological results. Among 120 patients
included in their study, 24 (20%) received extended tonsil-
lectomy, resulting in a higher rate (51%) of negative patho-
logical margins. The median RT dose was 66 Gy to the
primary site, and only 12 patients (10%) received chemo-
therapy. In the current study, pre-CRT tonsillectomy only
removed the primary tumors along the tonsil capsule or a cuff
of surrounding soft tissue without wide operative margins. As
mentioned earlier, only 20% of the patients in the pre-CRT
tonsillectomy group already had tissue diagnosis. Therefore,
as high as 80% of the patients in this group received the
surgery for diagnostic intent. This can explain the high posi-
tive margin rate in our study. Although chemotherapy was not
performed in 40% of the patients in the pre-CRT tonsillectomy
group, there was no reduction in the dose of RT compared with
the CRT group. The long-term benefit of omitting chemo-
therapy remained minimal in the current study.
Given that six (20%) of the 30 patients in the pre-CRT
tonsillectomy group already had a tissue diagnosis and 17
(56.7%) demonstrated gross visible tonsillar tumors, pre-CRT
tonsillectomy was performed mainly based on the belief that
optimal oncological outcomes can be achieved by reducingtumor burden before CRT treatment. However, this concept
was not supported by our data. In fact, the survival rate of the
pre-CRT tonsillectomy group in this study was poorer due to
the higher DM rate. It is plausible that the higher proportion of
patients receiving ICT in the CRT group may have contributed
to the lower DM rate. Because the roles of ICT in improving
distant control and survival are still inconclusive from ran-
domized control trials,19,20 this explanation should still be
regarded as hypothetical for this study.
Feeding and tracheostomy tube dependence have been used
as indicators of functional outcomes for patients treated with
CRT.21 Given the equivalent RT dose, it is not surprising that
the major complication, feeding tube and tracheostomy-
dependent rates were also similar between the two treatment
groups at 6 months posttreatment. The posttreatment QOL as
evaluated by the EORTC QLQ questionnaires in a small
subgroup of our patients also showed no significant differences
in most scales, indicating that pre-CRT tonsillectomy
contributed no advantage in posttreatment QOL. The only
trend of difference was observed with regard to fewer senses
problems in the EORTC QLQ-H&N 35 in the pre-CRT ton-
sillectomy group which included a higher percentage (40%) of
patients who did not receive chemotherapy (Table 5). Broglie
et al22 also recently demonstrated more senses problems and
dry mouth in patients undergoing primary CRT compared with
those treated with surgery and postoperative RT. It is possible
that the platinum-based chemotherapy caused dysgeusia due to
related neuropathy which contributed to the higher senses
problems scores in our CRT group.23
Because pre-CRT tonsillectomy was only minimally
beneficial in the current study, we suggest that a biopsy under
topical anesthesia should be the first choice for the diagnosis
of grossly visible tonsillar SCC. Pre-CRT tonsillectomy can
then be reserved for patients presenting with cervical metas-
tasis of unknown primary origin or suspicious asymmetric
tonsils to allow for a higher tumor detection rate.24e29
A major limitation of this study is the small sample size,
which resulted because we included only a homogenous pa-
tient cohort with early T1-T2 tonsillar SCCs. Owing to the
retrospective design, pre-CRT tonsillectomy was decided by
the surgeons according to the feasibility of removal and their
preference. Selection bias is also obvious, as seen by the
higher percentage of T1 patients in the pre-CRT tonsillectomy
group. In addition, patients with better performance status and
less comorbidity may also have been selected for pre-CRT
tonsillectomy. However, such bias toward favorable patients
may not have affected our conclusion that pre-CRT tonsil-
lectomy contributes little to oncological and functional results
of CRT treatment for early T1-T2 tonsillar SCCs. Another
limitation is that data on the HPV status of most patients in our
series (80.5%) were not available. It was not until 2005 that
HPV status was routinely checked in our department of pa-
thology. HPV has been demonstrated to be an indicator of
better outcomes in patients with oropharyngeal cancer treated
with CRT.30e32 Nevertheless, the prevalence of HPV tonsillar
SCC is relatively low (12.6%) in Taiwan compared with that in
Western countries.33 Future investigations should stratify
575Y.-T. Chao et al. / Journal of the Chinese Medical Association 79 (2016) 570e576patients by HPV status in order to minimize the confounding
effects on tumor control and survival.
In conclusion, pre-CRT tonsillectomy contributes little to
locoregional control and survival rates, because CRT already
provides excellent treatment results for patients with T1-T2
tonsillar SCC. Pre-CRT tonsillectomy did not reduce the fre-
quency of major complications or improve functional out-
comes and post-CRT QOL. Our results suggest that when CRT
is chosen as the primary treatment, pre-CRT tonsillectomy is
not necessary if the tumor is obviously visible or tissue
diagnosis has been obtained. Future studies should focus on
the benefits of novel surgical techniques, such as transoral
lateral oropharyngectomy or robotic surgery, in dein-
tensification or improving CRT treatment results.
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